Efficacy and Safety of Curcumin Supplement on Improvement of Insulin Resistance in People with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Background Diabetes is a major public health concern. In addition, there is some evidence to support curcumin as part of a diabetes treatment program.Methods Data from randomized controlled trials were obtained to assess the effects of curcumin versus placebo or western medicine in patients with type 2 diabetes mellitus (T2DM). The study's registration number is CRD42018089528. The primary outcomes included homeostasis model assessment-insulin resistance (HOMA-IR), glycosylated hemoglobin (HbAlc), total cholesterol (TC), and triglyceride (TG).Results Four trials involving 453 patients were included. The HOMA-IR of curcumin group is lower in Asia (WMD: −2.41, 95% CI: −4.44 to −0.39, P =0.02) and the Middle East subgroups (WMD: −0.60, 95% CI: −0.74 to −0.46, P < 0.00001). The HbAlc in the curcumin group is lower than that in the control group (WMD: −0.69; 95% CI: −0.91, −0.48; P < 0.0001). The TC and TG levels of the curcumin group are lower in the Asia subgroup (TC: WMD: −23.45, 95% CI: −40.04 to −6.84, P =0.006; TG: WMD: −54.14, 95% CI: −95.71 to −12.57, P =0.01), while in the Middle East the difference was of not statistically significant (TC: WMD: 22.91, 95% CI: −16.94 to 62.75, P =0.26; TG: WMD: −4.56, 95% CI: −19.28 to 10.16, P =0.54).Conclusion Based on the current evidence, curcumin may assist in improving the insulin resistance, glycemic control, and decreased TG and TC in patients with T2DM.